The infrequent simultaneous genetic alterations in glioblastoma multiforme (LOH 10, 17, 19q, TP53 mutation and EGFR amplification) with short clinical course

Polish Journal of Pathology

Volumn 58, Issue 2, 2007, Pages 79-85

  Jesionek Kupnicka, Dorota ^a   Kulczycka, D ^a   Rieske, P ^b   Szybka, M ^a   Jablonska J ^a   Potemski, P ^a   Kolasa, P ^c   Liberski, P P ^b   Kordek, R ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Department of Molecular Biology and Neuropathology ^*  (Poland)

^c N Copernicus Hospital   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; PROTEIN P53; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MALE; POLYMERASE CHAIN REACTION; RADIODIAGNOSIS;

BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 19; COMBINED MODALITY THERAPY; FATAL OUTCOME; GENE AMPLIFICATION; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; MUTATION, MISSENSE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34547168866     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Batchelor TT, Betensky RA, Esposito JM, Pham LD. Dorfman MV, Piscatelli N, Jhung S, Rhee D, Louis D: Age-dependent prognostic effects of genetic alterations in glioblastoma Clin Cancer Res 2004, 10, 228-233.
2. Biernat W, Debiec-Rychter M, Liberski PP: Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas. Pol J Pathol 1998, 49, 267-271.
3. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H: Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol (Berl) 1997, 94, 303-309.
4. kip1 by the Phosphoinositidc 3-Kinase Pathway in Glioblastoma Cells. J Biol Chem 2005, 280, 2012-2019.
5. Burger PC, Green SB: Patient age, histological features, and length of survival in patients with glioblastoma multiforme. Cancer [Phila.] 1987, 59, 1617-1625.
6. Burger PC, Pearl DK, Aldape K, Yates AJ, Scheithauer BW, Passe SM, Jenkins RB,James CD: Small cell architecture-a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 2001, 6, 1099-1104.
7. Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A, Loeffler JS: The prognostic significance of phosphatidylinositol 3-kipase pathway activation in human gliomas. J Clin Oncol 2004, 22, 1926-1933.
8. Cheng Y, Ng HK, Ding M, Zhang SF, Pang JC, Lo KW: Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors. J Neuropathol Exp Neurol 1999, 58, 120-128.
9. Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR, Nicholas MK, Stokoe D, Haas-Kogan DA: Dysregulation of PTEN and Protein Kinase B is associated with glioma histology and patient survival. Clin Cancer Res 2002, 8, 1100-1106.
10. Etienne MC, Formento JL, Lebrun-Frenay C, Gioanni J, Chatel M, Paquis P,Bernard C, Courdi A, Bensadoun RJ, Pignol JP, Francoual M, Grellier P, Frenay M, Milano G: Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 1998, 4, 2383-2390.
11. Fueller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, Yung WK, Zhang W: Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res 1999, 59, 4228-4232.
12. Fults D, Pedone C: Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme. Genes Chromosomes Cancer 1993, 7, 173-177.
13. Gottschalk AR, Basila D, Wong M, Dean NM, Brandts CH, Stokoe D, Haas-Kogan DA: p27 kip1 is required for PTEN-induced G1 growth arrest. Cancer Res, 2001, 61, 2105-2111.
14. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005, 97, 880-887.
15. He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S, Leuraud P, Capelle L, Delattre JY, Poirier J, Hoang-Xuan K: Glioblastomas with an oligodendroglial component: a pathological and molecular. Neuropathol Exp Neurol 2001, 60, 863-871.
16. Kamiryo T, Tada K, Shiraishi S, Shinojima N, Nakamura H, Kochi M, Kuratsu J, Saya H, Ushio Y: Analysis of homozygous deletion of the p16 gene and correlation with survival inpatients with glioblastoma multiforme. J Neurosurg 2002, 96, 815-822.
17. Kirla RM, Haapsalo HK, Kalimo H, Salminen EK: Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer 2001, 97, 644-648.
18. Kleihus P, Ohgaki H: Primary and secondary glioblastoma from concept to the clinical diagnosis. Neuro-Oncology, 1999, 1, 44-51.
19. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E: MDM2 and p53 expression in gliomas; a multivariate survival analysis including proliferation markers and epidermal growth factor receptor Br J Cancer 1997, 75, 1269-1278.
20. Kraus JA, Glesmann N, Beck M, Krex D, Klockgether T, Schackert G, Schlegel U: Molecular analysis of the PTEN, TP53 and CDKN2A tumor supressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol 2000, 48, 89-94.
21. Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, Krex D, Klockgether T, Reifenberger G, Schlegel U: Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol (Berl). 2001, 101, 311-320.
22. Lang FF, Miller DC, Koslow M, Newcomb EW: Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alteration in 65 astrocytic tumors. J Neurosurg 1994, 81, 427-436.
23. Leevers SJ, Vanhaesebroeck B, Waterfield MD: Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 1999, 11, 219-225.
24. Li D-M, Sun H: PTEN/MMAC1/TEP1 suppresses the tumorigenecity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 1998, 26, 15406-15411.
25. Louis DN: A molecular genetic model of astrocytoma histopathology. Brain Pathology 1997, 7, 755-764.
26. Maehama T, Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem 1998, 273, 13375-13378.
27. Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, Miller DC: Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Patol 1998, 8, 655-667.
28. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre P-L, Burkhard C, Schuller D, Probst-Hensch NM, Maiorka PC, Baeza N Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM, Kleihues P: Genetic pathways to glioblastoma: a population-based study. Cancer Rees 2004, 64, 6892-6899.
29. Okada Y, Hurwitz EE, Esposito JM, Brower MA, Nutt CL, Louis DN: Selection pressures of TP53 mutation and micrenvironmental location influence epidermal growth factor receptor gene amplification in human gliomas. Cancer Res 2003, 63, 413-416.
30. Peraud A, Watanabe K, Schweichheimeier K, Yonekawa Y, Kleihues P, Ohgaki H: Genetic profile of the giant cell glioblastoma. Lab Invest 1999, 79, 123-129.
31. Rieske P, Kordek R, Bartkowiak J, Dȩbiec-Rychter M, Biernat W, Liberski PP: A comparative study of epidermal growth factor receptor (EGFR) and MDM2 gene amplification and protein immunoreactivity in human glioblastomas. Pol J Pathol 1998, 49, 3, 145-149.
32. Rieske P, Zakrzewska M, Biernat W, Bartkowiak J, Zimmermann A, Liberski PP: Atypical molecular background of glioblastoma and meningioma developed in a patient with Li-Fraumeni syndrome. J Neurooncol 2005, 71, 27-30.
33. Sauter G, Maeda F, Waldman FM, Davis RL, Feurstein BG: Pattern of epidermal growth factor receptor amplification in malignant gliomas. Am J Pathol 1996, 148, 1047-1053.
34. Scott JN, Newcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M, Cairncross JG, Forsyth P: Which glioblastoma multiforme patient will become a long- term survivor? A population-based study. Ann Neurol. 1999, 46, 183-188.
35. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y, Ushio Y: Prognostic value of epdermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003, 63, 6962-6970.
36. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker II FG, Aldape K: Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001, 61, 1122-1128.
37. Smith JS, Tashibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001, 93, 1246-1256.
38. Tamiya T, Mizumatsu S, Ono Y, Abe T, Matsumoto K, Furuta T, Ohmoto T: High cyklin E/low p27Kip1 expression is associated with poor prognosis in astrocytomas. Acta Neuropathol [Berl] 2001, 101, 334-340.
39. Toyushima H, Hunter T: p27, a novel inhibitor of G1 cyclin Cdk protein kinase activity, is related to p21. Cell 1994, 78, 67-74.
40. Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, Fujimaki T, Hojo S, Kubo O, Ide T, Usui M, Ochiai Ch, ho S, Takahashi H, Mukasa A, Asai A and Kirino T: Correlation of Histology and Molecular Genetic Analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 Astrocytic and Oligodendroglial Tumors Clinical Cancer Research 2002, 8, 196-201.
41. Von Deimling A, Louis DN, Von Ammon K, Petersen I, Hoell T, Chung RY, Martuza RL, Schoenfeld DA, Yasargil G, Wiestler OD et al: Association of epidermal growth factor receptor gene amplification with luss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 1992, 77, 295-301.
42. Von Deimling A, Von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol, 3, 19-26, 1993.
43. Waha A, Baumann A, Wolf HK, Fimmers R, Neumann J, Kindermann D, Astrahantseff K, Blumcke I, von Deimling A, Schlegel U: Lack of prognostic relevance of alterations in epidermal growth factor receptor-transforming growth factor-α pathway in human astrocytic gliomas. J Neurosurg 1996, 85, 634-641.
44. Wang H, Wang H, Shen W, Huang H, Hu L, Ramdas L, Zhou Yi-H, Liao W S-L, Fuller GN, Zhang W: Insulin-like growth factor binding protein2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res, 2003, 63, 4315-4321.
45. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Patol, 1996, 6, 217-223.
46. Yao KC, Komata T, Kondo Y, Kanzawa T, Kondo S, Germano IM: Molecular response of human glioblastoma multiforme cells to ionizing radiation: cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors, and autophagy. J Neurosurg. 2003, 98, 378-384.
47. Zhang W, Wang H, Song SW, Fuller GN: Insulin-like growth factor binding protein 2: gene expression microarrays and the hypothesis-generation paradigm. Brain Pathol 2002, 12, 87-94.
48. Zhou XP, Li YJ, Hoang-Xuan K, Laurent-Puig P, Mokhtari K, Longy M, Samson M, Delattre JY, Thomas G, Hamelin R: Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 1999, 20, 150-154.
49. Zhu A, ShaefferJ, Leslie S, Kolm P, El-Mahdi AM: Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys 1996, 34, 809-815.